HEALTH● LOW3d ago · Oct 29, 2026, 1:37 PM
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
nynewsly · united states of america · western europe
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease1 The combination vaccine candidate evaluated in this trial pairs Sanofi’s leading high-dose flu vaccine with Novavax’s differentiated COVID-19 vaccine Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royalties GAITHERSBURG, […]
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapunited states of america and nearby eventsMore from united states of americaLatest stories and threat level
More in Health
HEALTH1h agoJohnson & Johnson reports 94% success rate in trial of coronary artery deviceSeeking Alpha TechHEALTH2h agoMillions of popular coffee makers at Walmart, Target recalled after dozens burnedThe Independent WorldHEALTH3h agoDo you know signs of a stroke? BE FAST are the words to rememberNPR NewsHEALTH6h agoConnecticut Senator Chris Murphy is hospitalized with a strokeNPR News